AbbVie Inc (ABBV)vsCastle Biosciences Inc (CSTL)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
CSTL
Castle Biosciences Inc
$19.83
+3.07%
HEALTHCARE · Cap: $583.55M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 18149% more annual revenue ($62.82B vs $344.23M). ABBV leads profitability with a 5.8% profit margin vs -7.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
CSTL
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.7%
Fair Value
$168.33
Current Price
$201.55
$33.22 premium
Margin of Safety
+65.9%
Fair Value
$94.72
Current Price
$19.83
$74.89 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
0.8% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : CSTL
The strongest argument for CSTL centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : CSTL
The primary concerns for CSTL are Revenue Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while CSTL is a turnaround play — different risk/reward profiles.
CSTL carries more volatility with a beta of 1.11 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 33/100) and 12.4% revenue growth. CSTL offers better value entry with a 65.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a cutting-edge diagnostics company dedicated to transforming patient care through its innovative gene-expression profiling tests, particularly in the realm of skin cancer. Its flagship product, DecisionDx®-Melanoma, is instrumental in the management of melanoma, providing critical insights into patient risk stratification and treatment decision-making. With a robust commitment to precision medicine, Castle is actively expanding its portfolio of assays to address unmet clinical needs. Bolstered by a strong research and development focus and an ambitious pipeline, the company is strategically positioned for sustainable growth while enhancing clinical outcomes and delivering significant value to its shareholders in the evolving oncology marketplace.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?